Source link : https://www.newshealth.biz/health-news/fda-expands-durvalumab-label-to-operable-lung-cancer/
The FDA expanded the labeling of the immunotherapy durvalumab (Imfinzi) on Thursday to include the perioperative treatment of resectable non-small cell lung cancer (NSCLC). Approved in combination with platinum-based chemotherapy during the neoadjuvant phase and as monotherapy during the adjuvant phase, the PD-L1 inhibitor is specifically indicated for tumors that are node-positive or at least […]
Author : News Health
Publish date : 2024-08-16 17:09:04
Copyright for syndicated content belongs to the linked Source.
Categories